• No results found

University of Groningen Imaging hormone receptors in metastatic breast cancer patients Venema, Clasina Marieke

N/A
N/A
Protected

Academic year: 2021

Share "University of Groningen Imaging hormone receptors in metastatic breast cancer patients Venema, Clasina Marieke"

Copied!
2
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

University of Groningen

Imaging hormone receptors in metastatic breast cancer patients

Venema, Clasina Marieke

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date: 2018

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Venema, C. M. (2018). Imaging hormone receptors in metastatic breast cancer patients. Rijksuniversiteit Groningen.

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

(2)

Stellingen behorende bij het proefschrift

1. De FES PET scan kan als surrogaat voor multipele biopten fungeren (Dit proefschrift)

2. De FES PET scan heeft meerwaarde bij een klinisch dilemma in patiënten met een lobulair mamma-carcinoom. (Dit proefschrift, v Kruchten et al. J Nucl Med 2012, Groheux et al. EJNMMI 2015)

3. Bij “precision medicin” in gemetastaseerde ziekte

wordt moleculaire beeldvorming belangrijk (Dit proefschrift, Kurland et al. Clin Cancer Res 2016) 4. FES opname in de longen kan passen bij longfibrose

(dit proefschrift)

5. De androgeen receptor in borstkanker is oud nieuws, maar geeft nu nieuwe inzichten. (Dit proefschrift)

6. Tijdens behandeling met de AR antagonist

bicalutamide kan de FDHT PET AR blokkade visualiseren en kwantificeren. (dit proefschrift) 7. De implementatie van PET scans in de reguliere zorg

voor patiënten met borstkanker vergt een

multidisciplinaire aanpak en uniforme

dataverzameling (dit proefschrift)

8. Gecombineerde FES en FDG PET scans geven inzicht in tumorbiologie en kunnen meer indolente tumoren onderscheiden van agressieve tumoren (Kurland Clin Cancer Res 2017)

9. Kosten verbonden aan diagnostiek moeten

meegewogen worden in de besluitvorming deze al dan niet in te zetten (Saltz, J Clin Oncol 2016). 10. Rotterdam: de allermooiste rotstad die er is. (Hermes

Referenties

GERELATEERDE DOCUMENTEN

Chapter 7 Androgen and estrogen receptor imaging in metastatic breast cancer patients as a surrogate for tissue biopsies. J Nucl Med 2017;

11 The purpose of our study therefore was to evaluate whether FDHT PET imaging in metastatic breast cancer can be used to predict early treatment response to bicalutamide.. Not

In ER- positive breast cancer patients that have high risk to develop metastases or have clinical signs, laboratory values or histology suggestive of the presence of

As this enhanced uptake was seen in the lungs and most patients were irradiated in the thoracic area, we hypothesized that pulmonary fibrosis as a result of earlier radiation

Because of the discrepancy between the different conventional imaging modalities, a FES-PET was performed, which showed high tracer uptake in multiple bone lesions and lymph

In this feasibility study, we investigated on a lesion by lesion basis whether non-invasive in vivo imaging of ER expression in metastatic breast cancer patients by means of

Overall survival rate (y-axis) in years (x-axis) according to mRNA profiling for oestrogen receptor (ER), androgen receptor (AR) and human epidermal growth factor receptor 2

Secondary endpoints were the optimum threshold to discriminate positive and negative lesions for both AR and ER on PET, inter- and intra-patient FDHT and FES heterogeneity, and